Sansure Biotech Inc (688289) - Total Assets
Based on the latest financial reports, Sansure Biotech Inc (688289) holds total assets worth CN¥9.64 Billion CNY (≈ $1.41 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sansure Biotech Inc - Total Assets Trend (2017–2025)
This chart illustrates how Sansure Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see Sansure Biotech Inc (688289) market capitalisation for the company's overall valuation and market capitalisation.
Sansure Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sansure Biotech Inc's total assets of CN¥9.64 Billion consist of 55.4% current assets and 44.6% non-current assets. Review 688289 liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 41.7% |
| Accounts Receivable | CN¥621.44 Million | 6.5% |
| Inventory | CN¥413.69 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥620.67 Million | 6.5% |
| Goodwill | CN¥798.39 Million | 8.4% |
Asset Composition Trend (2017–2025)
This chart illustrates how Sansure Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Sansure Biotech Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sansure Biotech Inc's current assets represent 55.4% of total assets in 2025, a decrease from 56.3% in 2017.
- Cash Position: Cash and equivalents constituted 41.7% of total assets in 2025, up from 7.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 8.4% of total assets.
Sansure Biotech Inc Competitors by Total Assets
Key competitors of Sansure Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Nextgen
TA:NXGN
|
Israel | ILA1.48 Million |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$2.77 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Sansure Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.67 | 4.66 | 9.44 |
| Quick Ratio | 4.25 | 4.30 | 8.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.98 Billion | CN¥4.23 Billion | CN¥5.49 Billion |
Sansure Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Sansure Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 10.7% |
| Total Assets | CN¥9.53 Billion |
| Market Capitalization | $1.40 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sansure Biotech Inc's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sansure Biotech Inc's assets grew by 10.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sansure Biotech Inc (2017–2025)
The table below shows the annual total assets of Sansure Biotech Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.53 Billion ≈ $1.39 Billion |
+10.73% |
| 2024-12-31 | CN¥8.60 Billion ≈ $1.26 Billion |
+1.77% |
| 2023-12-31 | CN¥8.45 Billion ≈ $1.24 Billion |
-7.84% |
| 2022-12-31 | CN¥9.17 Billion ≈ $1.34 Billion |
+29.38% |
| 2021-12-31 | CN¥7.09 Billion ≈ $1.04 Billion |
+29.99% |
| 2020-12-31 | CN¥5.45 Billion ≈ $798.15 Million |
+748.98% |
| 2019-12-31 | CN¥642.47 Million ≈ $94.01 Million |
+16.38% |
| 2018-12-31 | CN¥552.04 Million ≈ $80.78 Million |
-2.40% |
| 2017-12-31 | CN¥565.61 Million ≈ $82.77 Million |
-- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more